Table 1 Clinical trials of PARP inhibitor drugs for pancreatic cancer
From: PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
Trial ID | Therapeutic Drugs | Phase | Status | Treatment Setting | Primary Outcomes |
|---|---|---|---|---|---|
NCT02677038 | Olaparib | II | Recruiting | Metastatic PAC Patients must be germline BRCA 1 or 2 negative | Objective tumor response rate |
NCT02511223 | Olaparib | II | Unknown | Metastatic PAC with BRCA 1/2 mutations negative but loss of ATM | Objective response rate |
NCT01078662 | Olaparib | II | Active, not recruiting | Advanced tumors with BRCA1/2 mutation, including pancreatic cancer | Tumor response rate |
NCT02184195 | Olaparib Placebo | III | Active, not recruiting | Metastatic adenocarcinoma of the pancreas with germline BRCA1/2 mutations | Progression-free survival |
NCT01296763 | Olaparib Irinotecan Cisplatin Mitomycin-C | I | Completed | Advanced pancreatic cancer | Maximum-tolerated dose |
NCT00515866 | KU-0059436 (AZD2281) Gemcitabine | I | Completed | Advanced or metastatic unresectable PAC | Maximum-tolerated dose or tolerable and effective dose |
NCT03682289 | Olaparib ATR Kinase Inhibitor AZD6738 | II | Recruiting | Locally advanced or metastatic solid tumor malignancy, including pancreatic cancer | Objective response rate |
NCT03851614 | Olaparib Cediranib | II | Recruiting | Mismatch repair-proficient colorectal cancer Pancreatic adenocarcinoma Leiomyosarcoma | Genomic and immune biomarkers |
NCT02498613 | Olaparib Cediranib Maleate | II | Recruiting | Metastatic or unresectable malignancy, including PDAC | Objective response rate |
NCT03878524 | SMMART Therapy Including Olaparib | I | Not yet recruiting | Breast cancer Prostate cancer Pancreatic cancer Acute myelogenous leukemia | The number of participants to complete first dose of first SMMART therapy |
NCT00892736 | Veliparib | I | Completed | Solid tumors with BRCA1/2 mutations, including pancreatic cancer | Maximum-tolerated dose Dose-limiting toxicities Recommended phase II dose |
NCT01908478 | Veliparib Gemcitabine | I | Active, not recruiting | Pancreatic cancer | Maximum-tolerated dose |
NCT01489865 | ABT-888 mFOLFOX-6 | I and II | Active, not recruiting | Metastatic pancreatic cancer | Dose-limiting toxicities |
NCT02890355 | Veliparib Fluorouracil Irinotecan Hydrochloride Leucovorin Calcium | II | Active, not recruiting | Metastatic pancreatic adenocarcinoma, recurrent pancreatic carcinoma, stage IV pancreatic cancer | Overall survival |
NCT01585805 | Veliparib Cisplatin Gemcitabine Gemcitabine Hydrochloride | II | Active, not recruiting | Locally advanced or metastatic pancreas adenocarcinoma with a BRCA1/2 or PALB2 mutation | Optimal dose Response rate |
NCT01282333 | Veliparib Cisplatin Gemcitabine Hydrochloride | I | Terminated | Advanced biliary/pancreatic cancer, urothelial cancer, non-small cell lung cancer | Maximum-tolerated dose |
NCT02831179 | Veliparib Capecitabine Temozolomide | I | Withdrawn | Metastatic unresectable neuroendocrine tumors, non-functional pancreatic neuroendocrine tumors, pancreatic glucagonoma, pancreatic insulinoma | Maximum-tolerated dose |
NCT01233505 | Veliparib Capecitabine Oxaliplatin | I | Terminated | BRCA-related solid tumors, including pancreatic cancer | Dose-limiting toxicities Maximum-tolerated dose |
NCT00576654 | Veliparib Irinotecan Hydrochloride | I | Active, not recruiting | Malignant solid neoplasms, including pancreatic cancer | Optimal biologic dose |
NCT03140670 | Rucaparib | II | Recruiting | Locally advanced or metastatic pancreatic cancer | Number of adverse events |
NCT02042378 | Rucaparib | II | Completed | Pancreatic cancer, pancreatic ductal adenocarcinoma | Overall response rate |
NCT03337087 | Rucaparib Fluorouracil Leucovorin Calcium Liposomal Irinotecan | I and II | Recruiting | Pancreatic, colorectal, gastroesophageal or biliary adenocarcinoma | Maximum-tolerated dose |
NCT02711137 | Rucaparib INCB057643 Gemcitabine Paclitaxel Abiraterone Ruxolitinib Azacitidine | I and II | Terminated | Solid tumors, including pancreatic cancer | Safety and tolerability |
NCT01286987 | Talazoparib | I | Completed | Locally advanced or metastatic solid tumors, including pancreatic cancer | Number of participants with an objective response |
NCT02567396 | Talazoparib | I | Withdrawn | Metastatic or unresectable malignancies including pancreatic adenocarcinoma | Incidence of toxicity Recommended phase 2 dose Tolerability |
NCT03637491 | Talazoparib Avelumab Binimetinib | II | Recruiting | Locally advanced or metastatic solid tumors, pancreatic cancer | Dose-limiting toxicity |
NCT03601923 | Niraparib | II | Recruiting | Pancreatic cancer | Progression-free survival |
NCT03553004 | Niraparib | II | Recruiting | Pancreatic cancer | Objective response rate |
NCT03404960 | Niraparib + Nivolumab Niraparib + Ipilimumab | I and II | Recruiting | Pancreatic adenocarcinoma | Progression-free survival |
NCT02244489 | Momelotinib Capecitabine Oxaliplatin | I | Terminated | Relapsed/refractory metastatic pancreatic ductal adenocarcinoma | Incidence of dose-limiting toxicities Safety |
NCT02101021 | Momelotinib Placebo to match Momelotinib Nab-paclitaxel Gemcitabine | III | Terminated | Metastatic pancreatic ductal adenocarcinoma | Dose-limiting toxicity Overall survival |